Last reviewed · How we verify

NCT04262999

Bone Mineral Density and Periodontal Status in Patients on Antiepileptic Drug

Status unknown Last updated 10 February 2020
What this trial tests

trial testing effect of sodium valproate on alveolar bone level in Alveolar Bone Loss in 140 participants. Status unknown.

Timeline
1 January 2020
Primary endpoint
30 April 2021
30 April 2021

Quick facts

Lead sponsorPostgraduate Institute of Dental Sciences Rohtak
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment140
Start date1 January 2020
Primary completion30 April 2021
Estimated completion30 April 2021
Sites1 location across India

Drugs / interventions tested

Conditions studied

Sponsor

Postgraduate Institute of Dental Sciences Rohtak

Who can join

Adults 18 to 40, any sex, with Alveolar Bone Loss. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Assessment of bone mineral density and periodontal parameters in patients with epilepsy. Comparative evaluation of bone mineral density and levels of marginal alveolar bone in patients with epilepsy on monotherapy, combination therapy, and systemically healthy individuals.Comparative evaluation of periodontal parameters in all the patients who are on monotherapy and combination therapy and in systemically healthy individuals.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Alveolar Bone Loss

Currently open trials in the same condition.

Other Postgraduate Institute of Dental Sciences Rohtak trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04262999.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing